RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vivoryon Therapeutics Stock

Vivoryon Therapeutics ROCE 2024

Vivoryon Therapeutics ROCE

-1.1

Ticker

VVY.AS

ISIN

NL00150002Q7

WKN

A2QJV6

In 2024, Vivoryon Therapeutics's return on capital employed (ROCE) was -1.1, a -0.1% increase from the -1.1 ROCE in the previous year.

Vivoryon Therapeutics Aktienanalyse

What does Vivoryon Therapeutics do?

Vivoryon Therapeutics NV is a biopharmaceutical company specializing in the development of drugs for the treatment of Alzheimer's and other neurodegenerative diseases. The company was founded in 2016 in Leuven, Belgium and is headquartered in Heidelberg, Germany. Vivoryon Therapeutics has a history dating back to 2005 when it was supported by EFPIA-AIM. The company has since gone through several successful financing rounds to advance its research and development efforts. Its business model is based on the discovery and development of therapeutics with a new chemical approach to treating Alzheimer's and other neurodegenerative diseases. Vivoryon Therapeutics is currently involved in three different therapy areas: small molecule blockers, epigenetics, and big data analytics and telemetry technologies. The company is also developing a drug known as PQ912, which has the potential to slow down the progression of Alzheimer's disease. Vivoryon Therapeutics has partnerships and collaborations with various institutions to further its research and development programs. Overall, the company has the potential to revolutionize the treatment of Alzheimer's and other neurodegenerative diseases through its innovative efforts and collaborations. Vivoryon Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Vivoryon Therapeutics's Return on Capital Employed (ROCE)

Vivoryon Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Vivoryon Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Vivoryon Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Vivoryon Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Vivoryon Therapeutics stock

What is the ROCE (Return on Capital Employed) of Vivoryon Therapeutics this year?

The ROCE of Vivoryon Therapeutics is -1.1 undefined this year.

How has the ROCE (Return on Capital Employed) of Vivoryon Therapeutics developed compared to the previous year?

The ROCE of Vivoryon Therapeutics has increased by -0.1% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Vivoryon Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Vivoryon Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Vivoryon Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Vivoryon Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Vivoryon Therapeutics impact the company?

An increase in the ROCE of Vivoryon Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Vivoryon Therapeutics affect the company?

A decrease in ROCE of Vivoryon Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Vivoryon Therapeutics?

Some factors that can affect Vivoryon Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Vivoryon Therapeutics so important for investors?

The ROCE of Vivoryon Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Vivoryon Therapeutics take to improve the ROCE?

To improve the ROCE, Vivoryon Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Vivoryon Therapeutics pay?

Over the past 12 months, Vivoryon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vivoryon Therapeutics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Vivoryon Therapeutics?

The current dividend yield of Vivoryon Therapeutics is .

When does Vivoryon Therapeutics pay dividends?

Vivoryon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vivoryon Therapeutics?

Vivoryon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Vivoryon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vivoryon Therapeutics located?

Vivoryon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vivoryon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vivoryon Therapeutics from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Vivoryon Therapeutics pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Vivoryon Therapeutics in the year 2023?

In the year 2023, Vivoryon Therapeutics distributed 0 EUR as dividends.

In which currency does Vivoryon Therapeutics pay out the dividend?

The dividends of Vivoryon Therapeutics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vivoryon Therapeutics

Our stock analysis for Vivoryon Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vivoryon Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.